Global Menopausal Hot Flashes Market Growth, Share, Size, Overview Report, Forecast 2034

Menopausal Hot Flashes Market Size And Industry Analysis

The global menopausal hot flashes market size was worth around USD 8.76 Billion in 2024 and is predicted to grow to around USD 16.22 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 6.35% between 2025 and 2034. The report analyzes the menopausal hot flashes market's drivers, restraints/challenges, and their effect on the demands during the projection period. In addition, the report explores emerging opportunities in the menopausal hot flashes market.

Request Free Sample

Menopausal Hot Flashes Market: Overview

Menopause is patent by hot flashes, which are the furthermost common. Hot flashes are thought to result from changes in the hypothalamus, the part of the brain that regulates body temperature; However, the exact reason is still unknown. The rise of postmenopausal symptoms due to the shift to a sedentary lifestyle is expected to drive the market. The increasing incidence of vasomotor and menopausal symptoms such as night sweats and hot flashes among women during the menopausal transition is expected to drive market growth. In addition, problems such as mood swings, difficulty concentrating, and depression are associated with menopause. In addition, increased investment in treating menopausal manifestations is expected to boost the market.

COVID-19 Impact:

The COVID-19 pandemic has impacted the businesses of menopausal hot flashes. The COVID-19 pandemic spread throughout the world as strict lockdowns are implemented by governments and shut down companies. Thus, the movement of people is restricted during the COVID-19 pandemic; the global menopausal hot flashes market is likely to be impacted considerably during the forecast period.

Key Insights

• As per the analysis shared by our research analyst, the global menopausal hot flashes market is estimated to grow annually at a CAGR of around 6.35% over the forecast period (2025-2034).
• Regarding revenue, the global menopausal hot flashes market size was valued at around USD 8.76 Billion in 2024 and is projected to reach USD 16.22 Billion by 2034.
• The menopausal hot flashes market is projected to grow at a significant rate due to increasing aging female population, rising awareness of menopause-related conditions, and development of hormone and non-hormonal treatment options.
• Based on Therapeutic Approach, the Hormonal Treatment (Estrogen segment is expected to lead the global market.
• On the basis of Formulation, the Oral segment is growing at a high rate and will continue to dominate the global market.
• Based on the Demographic Factors, the Age Group segment is projected to swipe the largest market share.
• Based on region, North America is predicted to dominate the global market during the forecast period.

Global Menopausal Hot Flashes Market: Report Scope

Menopausal Hot Flashes Market: Report Scope    

To know more about this report, request a sample copy.

Menopausal Hot Flashes Market: Growth Drivers

The increasing prevalence of menopausal hot flashes aids the global market growth

The main driving factors of the global menopausal hot flashes market are the increasing prevalence of menopausal hot flashes, the growing number of new pharmacological approvals for the treatment, and increasing health awareness. Hot flashes are a rapid feeling of heat that mainly affects the chest, neck, and face. Some key variables driving the strong growth of the menopausal hot flashes market are the frequency of fluctuations in high estrogen levels and impaired musculoskeletal health in women. As a result, healthcare companies are stepping up clinical studies of hormone-free products to meet various needs.

Menopausal Hot Flashes Market: Restraints

The side effects related to menopausal hot flashes may hamper the global market growth

The key restraints for the menopausal hot flashes market are the side effects of menopausal hot flashes, such as vaginal bleeding, hip & vertebral fractures, dementia, urinary incontinence, breast cancer, heart attack, blood clots, stroke, and colon cancer rectal. Because of these side effects, patients seek safer treatments such as herbal products and supplements, a major restraint that is expected to impede the growth of the global menopausal hot flashes market during the forecast period.

Menopausal Hot Flashes Market: Opportunities

The advancements by market players bring up several growth opportunities

Companies in the global menopausal hot flashes market recommend lifestyle changes for women through online media. Likewise, companies are developing innovative devices tailored to the needs of women. For example, the introduction of the Monopod has fueled the growth of the menopause flash market due to its compact mouse-like shape and portability. The advent of smartwatch-type devices that act as personal thermostats for women is also driving the global market.

Menopausal hot flashes Market: Segmentation Analysis

The global menopausal hot flashes market is segregated based on treatment type, distribution channel, and region.

By treatment type, the market is divided into hormonal treatment, non-hormonal treatment, and alternative treatment. Among these, in 2021, the hormonal treatment segment dominated the market, accounting for a significant percentage of global sales due to the increasing demand for menopausal hot flashes treatment. Also, it will grow with the highest CAGR during the forecast period.

By distribution channel, the market is categorized into retail pharmacies, hospital pharmacies, and online pharmacies. Over the forecast period, the hospital pharmacies segment is expected to develop at the fastest rate due to the increased checkups in hospitals.

Request Free Sample

Recent Developments

• December 2021 - Acer Therapeutics Inc. was approved by the U.S. Food and Drug Administration (FDA) for the registration of Investigative New Drugs (IND) for the selective neurokinin 3 (NK3R) non-peptide receptor antagonist, ACER-801 (osanetant) for the potential treatment of Induced Vasomotor Symptoms (iVMS).
• February 2021 - Astella Pharma Inc. published positive results from the pivotal phase 3 clinical trials of SKYLIGHT 1 and SKYLIGHT 2 or fezolintant, a non-hormonal oral compound being studied for the treatment of central vasomotor symptoms. Moderate to severe (VMS) (hot flashes associated with menopause).

Menopausal Hot Flashes Market: Regional Landscape

The growing population of geriatric women helps North America dominate the global market

North America is leading the global menopausal hot flashes market due to the growing population of geriatric women with menopausal symptoms in the United States and Canada. This industry is expected to grow to meet the increasing demand for medical treatments during hot flashes. According to the National Center for Biotechnology Information (NCBI), about 85% of postmenopausal women have experienced symptoms related to menopause (hot flashes).

According to the North American Menopause Society, about 75% of North American women experience hot flashes during perimenopause. Nearly a quarter of them are so bothered that they need to see a doctor. Menopause is common among older women, increasing the market's overall growth rate. In addition, technical improvements in the production of new pharmaceuticals, increased spending on healthcare and the presence of a well-established healthcare infrastructure all contribute to the market's growth.

Menopausal Hot Flashes Market: Competitive Landscape

The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the menopausal hot flashes market on a global and regional basis.

Some of the main competitors dominating the global menopausal hot flashes market include -

• Pfizer Inc.
• Novartis AG
• Novo Nordisk A/S
• Allergan plc
• Teva Pharmaceutical Industries Ltd
• Mylan N.V.
• Hisamitsu Pharmaceutical Co. Inc.
• Merck & Co. Inc.
• GlaxoSmithKline plc
• TherapeuticsMD Inc.

The global menopausal hot flashes market is segmented as follows:

By Treatment Type

• Hormonal Treatment
• Non-hormonal Treatment
• Alternative Treatment

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa